Table 1. Characteristics of ALL samples and derived xenografts.
| N | % | |
|---|---|---|
| Total | 23 | 100 |
| Patient characteristics | ||
| Gender | ||
| Female | 10 | 43 |
| Male | 13 | 57 |
| Age | ||
| 1–9 years | 15 | 65 |
| 0–1 and >9 years | 8 | 35 |
| Immunophenotype | ||
| pro-B ALL | 2 | 9 |
| c-ALL | 14 | 61 |
| pre-B ALL | 7 | 30 |
| Fusion gene | ||
| ETV6-RUNX1 | 4 | 17 |
| BCR/ABL | 1 | 4 |
| MLL rearrangement | 2 | 9 |
| No | 16 | 70 |
| Prednisone response | ||
| Good | 22 | 96 |
| Poor | 1 | 4 |
| Day 15, blast cell persistence | ||
| >5% | 7 | 30 |
| <5% | 7 | 30 |
| Not available | 9 | 40 |
| BFM risk groups | ||
| Non-HR | 19 | 83 |
| HR | 4 | 17 |
| Relapsea | ||
| Yes | 5 | 22 |
| No | 18 | 78 |
| Xenograft characteristics | ||
| Time to leukemia (TTL) | ||
| Long | 16 | 70 |
| Short | 7 | 30 |
| CRAC | ||
| Positive | 16 | 70 |
| Negative | 7 | 30 |
| NOD/SCID passage used for CRAC-analysis | ||
| P 0 | 1 | 4 |
| P 1 | 8 | 36 |
| P 2 | 6 | 26 |
| P 3 | 4 | 17 |
| P 4 | 2 | 9 |
| P 5 | 1 | 4 |
| P 6 | 1 | 4 |
Abbreviations: ABL, abelson oncogene; ALL, acute lymphoblastic leukemia; BCR, breakpoint cluster region; BFM, Berlin Frankfurt Münster study group; CRAC, cytochrome c-related activation of caspase-3; ETV6, ETS (E-twenty six) variant 6; MLL, mixed lineage leukemia; NOD, non-obese diabetic; RUNX1, runt-related transcription factor 1; SCID, severe combined immuno-deficiency; TTL, time to leukemia.
a
Death in remission while on therapy, n=1; observation time <24 months, n=1.